The FDA record for K254214 identifies Taiwan Main Orthopaedic Biotechnology Co., Ltd. as the applicant for a device named OOOPDS, filed under product code LLZ in the radiology advisory committee, with a Traditional 510(k) submission received December 29, 2025 and decided September 15, 2026. The same record lists a Taichung, Taiwan address and Jacky Fan as contact. A separate FDA letter names the company as applicant for Caduceus S under product code OLO. [1][6][8]
What the K254214 record establishes
K254214 covers OOOPDS, classified under 21 CFR 892.2050 with product code LLZ and a device class of 2, reviewed by the radiology advisory committee. The decision code is SESE, described as Substantially Equivalent, and the submission is marked Traditional with no third-party review. The record states that a summary is available rather than only a statement. [1][6]
The filing lists a Taichung, Taiwan address and contact Jacky Fan, with a decision date of September 15, 2026. These are filing details, not a verified corporate headquarters. [1]
OOOPDS as described by its publisher
Surglasses, publishing as the company's brand site, describes OOOPDS as the Orthopedic Operation and Object Planning Digital System and reports the FDA clearance under number K254214 alongside a US invention patent, in a news item dated November 10, 2026. The same publisher groups the product with preoperative planning, simulation and 3D printing functions, and describes navigation data presented in the surgeon's line of sight with C-arm, ultrasound and endoscope views. [3]
A device description associated with K254214 states that a physical model printed from an output file is used only to print unaltered anatomical structure, is not for diagnostic use, does not contact the patient and is not intended for use in a surgical environment. That scope limits what the printed output is documented to do. [6]
Earlier clearance and related product line
An FDA substantial equivalence letter dated December 16, 2022 addresses Taiwan Main Orthopaedic Biotechnology Co., Ltd. for trade device Caduceus S under 21 CFR 882.4560, Stereotaxic Instrument, Class II, product code OLO, with Min-Liang Wang identified as CEO and Jacky Fan as regulatory contact. That letter is a separate filing from K254214 and covers a different device and regulation. [8]
The company's brand site presents Caduceus S as an AR navigation system with a headset and a navigation cart, and lists 2D C-arm, 3D C-arm and intraoperative CT modules on one cart. These are publisher descriptions of the product line, not FDA findings in K254214. [4]
How to read the filing collection
The supplied collection, as of November 20, 2026, links one record, a 510(k) with decision SESE, and the smaller record sample contains that same single entry, K254214. The sample decision count of one SESE therefore describes the sample, not a broader portfolio, and the collection is not evidence of total company filings, sales or safety performance. [1]
Other FDA pages in the public documentation, including TPLC listings for other manufacturers and a separate premarket notification, do not document filings by this applicant and are not counted here. [5][7][9]

